BELLICUM PHARMACEUTICALS, INC 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Jul 6, 2017
Insider Transaction Report
Form 4
Moseley Ken
Vice President
Transactions
- Award
Stock Option (right to buy)
2017-07-03+26,250→ 26,250 totalExercise: $11.70Exp: 2027-07-02→ Common Stock (26,250 underlying) - Award
Stock Option (right to buy)
2017-07-03+42,000→ 42,000 total(indirect: Annemarie Moseley, Ph.D., M.D.)Exercise: $11.70Exp: 2027-07-02→ Common Stock (42,000 underlying)
Footnotes (2)
- [F1]25% of the shares subject to the stock option vest and become exercisable on January 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- [F2]The Reporting Person's spouse is Annemarie Moseley, Consultant to Bellicum, formerly COO/EVP Clinical Development. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.